Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: Perspectives and best practices derived from experienced treatment centres

Haemophilia

Volumn 18, Issue 6, 2012, Pages 971-981

  Escobar, M ^a   Maahs, J ^b   Hellman, E ^c   Donkin, J ^d   Forsyth, A ^e   Hroma, N ^f   Young, G ^d   Valentino, L A ^g   Tachdjian, R ^h   Cooper, D L ⁱ   Shapiro, A D ^b  

^a Gulf States Hemophilia and Thrombophilia Center   (United States)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^c Indiana Orthopedic Hospital   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Penn Hemophilia and Thrombosis Program   (United States)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NOVO NORDISK INC   (United States)

Author keywords

Congenital haemophilia; Inhibitors; Orthopaedic; Physical therapy; rFVIIa; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SEVEN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; DRUG MEGADOSE; HEALTH CARE PERSONNEL; HEMOPHILIA; HEMOSTASIS; HUMAN; MEDICAL PRACTICE; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT PLANNING; UNITED STATES;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTOR INHIBITORS; COMPREHENSIVE HEALTH CARE; FACTOR VIIA; HEMORRHAGE; HUMANS; JOINT DISEASES; POSTOPERATIVE CARE; PREOPERATIVE CARE; QUALITY ASSURANCE, HEALTH CARE; RECOMBINANT PROTEINS; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84868199179     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02894.x     Document Type: Article

References (64)

1. Peacock K. Quality of life before and after surgery: mobility issues, the fear of surgery, inpatient recovery and outpatient rehabilitation. Haemophilia 2005; 11(Suppl 1): 30-1.
2. World Federation of Hemophilia. Guidelines for the Management of Hemophilia.
3. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
4. Scalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
5. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
6. Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Fernandez I, Hernandez-Navarro F. Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors. Semin Hematol 2008; 45: S64-S67.
7. Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature. Haemophilia 2011; 17: 910-19.
8. Heisel MA, Gomperts ED, McComb JG, Hilgartner M. Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 1983; 102: 951-4.
9. Tourbaf KD, Dunlap BE, Ambrus JL, Rodman DJ, Atwal AJ. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor. J Med 1982; 13: 399-410.
10. Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
11. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26(Suppl 1): 118-23.
12. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
13. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
14. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery.Results from an open-label, randomized, multicenter trial.. Thromb Haemost 2007; 98: 726-32.
15. Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 2008; 14: 233-41.
16. Rodriguez-Merchan EC, Rocino A, Ewenstein B et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 2004; 10(Suppl 2): 50-2.
17. Rodriguez-Merchan EC, Quintana M, De lC-R, Coya J. Radioactive synoviorthesis for the treatment of haemophilic synovitis. Haemophilia 2007; 13(Suppl 3): 32-7.
18. Rodriguez-Merchan EC, Jimenez-Yuste V, Gomez-Cardero P, varez-Roman M, Martin-Salces M, Rodriguez de la RA. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia 2010; 16: 84-8.
19. Balkan C, Karapinar D, Aydogdu S et al.Surgery in patients with haemophilia and high responding inhibitors: Izmir experience. Haemophilia 2010; 16: 902-9.
20. Lauroua P, Ferrer AM, Guerin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia 2009; 15: 1300-7.
21. Takedani H, Kawahara H, Kajiwara M. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. Haemophilia 2010; 16: 290-5.
22. Valentino LA, Cooper DL, Goldstein B. Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011; 17: 579-89.
23. Giangrande PL, Wilde JT, Madan B et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009; 15: 501-8.
24. Teitel JM, Carcao M, Lillicrap D et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227-39.
25. Shapiro A, Cooper DL. U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors. Haemophilia 2012; 18: 400-5.
26. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, Hernandez-Navarro F. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia 2007; 13: 613-9.
27. Alioglu B, Ozsoy H, Koca G et al.The effectiveness of radioisotope synovectomy for chronic synovitis in Turkish paediatric haemophiliacs: Ankara experience. Haemophilia 2010; 16: 932-6.
28. Soroa VE, del HV, Giannone C et al. Effects of radiosynovectomy with p-32 colloid therapy in hemophilia and rheumatoid arthritis. Cancer Biother Radiopharm 2005; 20: 344-8.
29. Thomas S, Gabriel MB, Assi PE et al.Radioactive synovectomy with Yttrium citrate in haemophilic synovitis: Brazilian experience. Haemophilia 2011; 17: e211-e216.
30. Stephensen D. Rehabilitation of patients with haemophilia after orthopaedic surgery: a case study. Haemophilia 2005; 11(Suppl 1): 26-9.
31. Lobet S, Pendeville E, Dalzell R et al.The role of physiotherapy after total knee arthroplasty in patients with haemophilia. Haemophilia 2008; 14: 989-98.
32. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004; 10(Suppl 2): 30-40.
33. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg BM, Nilsson IM. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
34. Habermann B, Hochmuth K, Hovy L, Scharrer I, Kurth AH. Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience. Haemophilia 2004; 10: 705-12.
35. FEIBA NF [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2011.
36. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
37. Shapiro AD. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 2008; 6: 579-86.
38. Pan-Petesch B, Laguna P, Mital A et al.Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia 2009; 15: 760-5.
39. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
40. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
41. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
42. Morfini M, Bjerre J. Pharmacokinetics and safety of a 270 mcg kg(-1) dose of room temperature stable recombinant activated factor VII in patients with haemophilia. Haemophilia 2011; 17: 860-6.
43. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
44. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
45. Economou M, Teli A, Tzantzaroudi A, Tsatra I, Zavitsanakis A, thanassiou-Metaxa M. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding. Haemophilia 2008; 14: 390-1.
46. Miranda GG, Rodgers GM. Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA. Haemophilia 2009; 15: 383-5.
47. NovoSeven RT [package insert]. Princeton, NJ: Novo Nordisk Inc., 2010.
48. Villar A, Jimenez-Yuste V, Quintana M, Hernandez-Navarro F. The use of haemostatic drugs in haemophilia: desmopressin and antifibrinolytic agents. Haemophilia 2002; 8: 189-93.
49. Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A. Proposal of a standard approach to dental extraction in haemophilia patients A case-control study with good results. Haemophilia 2000; 6: 533-6.
50. Geerts WH, Bergqvist D, Pineo GF et al.Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
51. Butcher JH, Pasi KJ. Fatal postoperative pulmonary embolism in mild haemophilia. Haemophilia 2006; 12: 179-82.
52. Dargaud Y, Cruchaudet BB, Lienhart A, Coppere B, Ninet J, Negrier C. Spontaneous proximal deep vein thrombosis in a patient with severe haemophilia A. Blood Coagul Fibrinolysis 2003; 14: 407-9.
53. Girolami A, Scandellari R, Zanon E, Sartori R, Girolami B. Non-catheter associated venous thrombosis in hemophilia A and B A critical review of all reported cases. J Thromb Thrombolysis 2006; 21: 279-84.
54. Kashyap R, Sharma LM, Gupta S, Saxena R, Srivastava DN. Deep vein thrombosis in a patient with severe haemophilia A. Haemophilia 2006; 12: 87-9.
55. Stewart AJ, Manson LM, Dennis R, Allan PL, Ludlam CA. Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A. Haemophilia 2000; 6: 47-9.
56. Zakarija A, Aledort L. How we treat: venous thromboembolism prevention in haemophilia patients undergoing major orthopaedic surgery. Haemophilia 2009; 15: 1308-10.
57. Hermans C, Hammer F, Lobet S, Lambert C. Subclinical deep venous thrombosis observed in 10% of hemophilic patients undergoing major orthopedic surgery. J Thromb Haemost 2010; 8: 1138-40.
58. De KP, Blamey G, Zourikian N, Dalzell R, Lobet S. Physiotherapy following elective orthopaedic procedures. Haemophilia 2006; 12(Suppl 3): 108-12.
59. Ludlam C. Identifying and managing inhibitor patients requiring orthopaedic surgery - the multidisciplinary team approach. Haemophilia 2005; 11(Suppl 1): 7-10.
60. Konkle BA, Nelson C, Forsyth A, Hume E. Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia 2002; 8: 706-10.
61. Solimeno LP, Perfetto OS, Pasta G, Santagostino E. Total joint replacement in patients with inhibitors. Haemophilia 2006; 12(Suppl 3): 113-6.
62. Gringeri A, Fischer K, Karafoulidou A, Klamroth R, Lopez-Fernandez MF, Mancuso E. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
63. Riley RR, Witkop M, Hellman E, Akins S. Assessment and management of pain in haemophilia patients. Haemophilia 2011; 17: 839-45.
64. Wang D, Jones MH, Khair MM, Miniaci A. Patient-reported outcome measures for the knee. J Knee Surg 2010; 23: 137-51.